PDF(Pubmed)
Abstract：
BACKGROUND: Dravet Syndrome (DS) is a rare and severe form of childhood epilepsy that is often refractory to conventional antiepileptic drugs. Emerging evidence suggests that Cannabidiol (CBD) offer therapeutic benefits for DS. This review aims to evaluate the efficacy and safety of CBD in pediatric patients with DS based on data from ten clinical trials.
METHODS: A review was conducted to identify clinical trials assessing the efficacy and safety of CBD in pediatric patients diagnosed with DS. PubMed, MEDLINE, Scopus, Web of Science, and relevant grey literature were systematically searched for relevant articles up to October 2023, and clinical trials within the last 10 years were included. The search strategy incorporated controlled vocabulary terms and keywords related to \"Cannabidiol,\" \"Dravet Syndrome,\" and \"pediatric patients.\"
RESULTS: The analysis revealed promising efficacy outcomes. Notably, CBD demonstrated substantial reductions in seizure frequency, with some patients achieving seizure freedom. The findings emphasised the consistency of CBD\'s efficacy across different patient subgroups. The safety profile of CBD was generally acceptable, with adverse events often being manageable.
CONCLUSIONS: This review consolidates evidence from multiple clinical trials, affirming the potential of CBD as a promising treatment option for pediatric patients with DS. While further research is needed to address existing knowledge gaps, CBD\'s efficacy and acceptable safety profile make it a valuable addition to the therapeutic tools for DS.
METHODS: A review was conducted to identify clinical trials assessing the efficacy and safety of CBD in pediatric patients diagnosed with DS. PubMed, MEDLINE, Scopus, Web of Science, and relevant grey literature were systematically searched for relevant articles up to October 2023, and clinical trials within the last 10 years were included. The search strategy incorporated controlled vocabulary terms and keywords related to \"Cannabidiol,\" \"Dravet Syndrome,\" and \"pediatric patients.\"
RESULTS: The analysis revealed promising efficacy outcomes. Notably, CBD demonstrated substantial reductions in seizure frequency, with some patients achieving seizure freedom. The findings emphasised the consistency of CBD\'s efficacy across different patient subgroups. The safety profile of CBD was generally acceptable, with adverse events often being manageable.
CONCLUSIONS: This review consolidates evidence from multiple clinical trials, affirming the potential of CBD as a promising treatment option for pediatric patients with DS. While further research is needed to address existing knowledge gaps, CBD\'s efficacy and acceptable safety profile make it a valuable addition to the therapeutic tools for DS.
摘要：
背景：Dravet综合征（DS）是一种罕见且严重的儿童癫痫，通常对常规抗癫痫药物难以治疗。新的证据表明，大麻二酚（CBD）为DS提供治疗益处。这篇综述旨在根据来自10项临床试验的数据评估CBD在DS儿科患者中的疗效和安全性。
方法：进行了综述，以确定评估CBD在诊断为DS的儿科患者中的疗效和安全性的临床试验。PubMed,MEDLINE,Scopus,WebofScience,和相关灰色文献进行了系统搜索，以查找截至2023年10月的相关文章，并纳入了最近10年的临床试验。搜索策略包含与“大麻”相关的受控词汇术语和关键字，\"\"Dravet综合征,“和”儿科患者。\"
结果：分析显示有希望的疗效结果。值得注意的是,CBD显示癫痫发作频率大幅减少，一些患者实现了癫痫发作的自由。研究结果强调了不同患者亚组之间CBD疗效的一致性。CBD的安全性通常是可以接受的，不良事件通常是可控的。
结论：本综述整合了多项临床试验的证据，肯定CBD作为DS儿科患者有希望的治疗选择的潜力。虽然需要进一步的研究来解决现有的知识差距，CBD的疗效和可接受的安全性使其成为DS治疗工具的重要补充。
方法：进行了综述，以确定评估CBD在诊断为DS的儿科患者中的疗效和安全性的临床试验。PubMed,MEDLINE,Scopus,WebofScience,和相关灰色文献进行了系统搜索，以查找截至2023年10月的相关文章，并纳入了最近10年的临床试验。搜索策略包含与“大麻”相关的受控词汇术语和关键字，\"\"Dravet综合征,“和”儿科患者。\"
结果：分析显示有希望的疗效结果。值得注意的是,CBD显示癫痫发作频率大幅减少，一些患者实现了癫痫发作的自由。研究结果强调了不同患者亚组之间CBD疗效的一致性。CBD的安全性通常是可以接受的，不良事件通常是可控的。
结论：本综述整合了多项临床试验的证据，肯定CBD作为DS儿科患者有希望的治疗选择的潜力。虽然需要进一步的研究来解决现有的知识差距，CBD的疗效和可接受的安全性使其成为DS治疗工具的重要补充。
